Clinical trial NCT00501670: VZV PCR Sampling Validation Study
Official title: A Non-therapeutic Study to Validate the Sampling Method to Confirm Presence of Varicella-zoster Virus (VZV) DNA by PCR in Clinical Samples From Lesions Collected From Adults (≥50 Years) With Clinically Diagnosed Herpes Zoster
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Herpes Zoster
Keywords: Herpes zoster
PCR
Varicella zoster Virus (VZV)
Shingles
GSK Biologicals
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2007-07-16
Enrollment: 41
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: German male or female patients aged 50 years or older who are clinically diagnosed with HZ by the investigator including the presence of a typical HZ rash.

Brief summary: This study will evaluate and compare various methods for collecting lesion samples from subjects with clinically diagnosed herpes zoster for the laboratory confirmation of herpes zoster. The samples will be tested by polymerase chain reaction (PCR) to detect VZV DNA. Multiple samples from each type of herpes zoster lesion will be collected in order to determine whether the analysis of duplicate samples enhances the sensitivity of VZV DNA detection for the diagnosis of herpes zoster. In addition, blood will be collected for the evaluation of VZV immunity at the time of the initial herpes zoster sample collection (after herpes zoster has been clinically diagnosed) and one month later in order to establish the range of cellular and humoral immune responses during natural herpes zoster in adults ≥50 years old.

Detailed description: This non-prophylactic, non-therapeutic study involves NO treatment of study participants.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Eligibility criteria: Inclusion Criteria:

* Clinically diagnosed with herpes zoster by the investigator including the presence of a typical herpes zoster rash.
* A male or female aged 50 years or older at the time of the subject's enrolment.
* Written informed consent obtained from the subject.
* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.

Exclusion Criteria:

* Any malignancy for which the subject is receiving active treatment, or any haematological malignancy.
* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within three months prior to the first vaccination, including corticosteroids, except inhaled and topical steroids are allowed.
* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
* Previous vaccination against herpes zoster.
* Confirmed or suspected immunosuppression, based on medical history or physical examination (no laboratory testing required).
* A family history of congenital or hereditary immunodeficiency.
* History of or chronic alcohol or drug abuse.

Primary outcomes:
measure: Number of VZV DNA copies per clinical sample collected.
timeFrame: At the time of the clinical diagnosis of HZ (Month 0).
measure: Number of HSV DNA copies per clinical sample collected.
timeFrame: At the time of the clinical diagnosis of HZ (Month 0).
measure: Number of actin DNA copies per clinical sample collected.
timeFrame: At the time of the clinical diagnosis of HZ (Month 0).
Secondary outcomes:
measure: Frequencies of CD4/CD8 T cells with antigen-specific IFN-g and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE.
timeFrame: At Months 0 and 1.
measure: Frequencies of CD4/CD8 T cells with antigen-specific IFN-g and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to VZV.
timeFrame: At Months 0 and 1.
measure: Anti-gE Ab concentrations.
timeFrame: At Months 0 and 1.
measure: Anti-VZV Ab concentrations.
timeFrame: At Months 0 and 1.
measure: Frequencies of gE-specific memory B cells.
timeFrame: At Months 0 and 1.
measure: Frequencies of VZV-specific memory B cells.
timeFrame: At Months 0 and 1.
measure: Occurrence of all SAEs.
timeFrame: During the whole study period.
Other outcomes:
Locations:
city: Husum
country: Germany
facility: GSK Investigational Site
state: Schleswig-Holstein
city: Kiel
country: Germany
facility: GSK Investigational Site
state: Schleswig-Holstein
city: Hamburg
country: Germany
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: